Parkinson disease

123I-MIBG in Parkinson e scompenso cardiaco

123I-MIBG in Parkinson e scompenso cardiaco

Il gruppo di ricerca si occupa dell'utilizzo del radiofarmaco 123I-MIBG, Mataiodiobenzilguanidina,  per la diagnosi differenziale di Morbo di Parkinson in ambito neurologico e per il rischio di aritmie in pazienti con scompenso cardiaco. Questo analogo della noradrenalina radiomarcato con Iodio123 viene utilizzato in medicina nucleare per varie tipologie di pazienti, ed è in aumento il suo interesse scientifico per le potenzialità sia diagnostiche precoci che prognostiche.

Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease among the elderly. To understand pathogenesis and to test therapies, animal models that faithfully reproduce key pathological PD hallmarks are needed. As a prelude to developing a model of PD, we tested the tropism, efficacy, biodistribution, and transcriptional impact of canine adenovirus type 2 (CAV-2) vectors in the brain of Microcebus murinus, a nonhuman primate that naturally develops neurodegenerative lesions.

MAO inhibitors and their wider applications: a patent review

INTRODUCTION:
Monoamine oxidase (MAO) inhibitors, after the initial 'golden age', are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative diseases (selective MAO-B inhibitors). However, the research within this field is always increasing due to their pivotal role in modulating synaptic functions and monoamines metabolism.
AREAS COVERED:

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma